查看完整行情页>>

|

货币单位:美元(USD)

ContraVir Pharmaceuticals, Inc. (ctrv)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
John P. Brancaccio John P. Brancaccio is on the board of Tamir Biotechnology, Inc. and 4 other companies. In his past career Mr. Brancaccio held the position of Chief Operating & Financial Officer for Eline Entertainment Group, Inc., Chief Financial Officer at Orchestra Medical Ventures LLC, Chief Financial Officer, Secretary & Treasurer of Memory Pharmaceuticals Corp. and Chief Financial Officer at Accelerated Technologies, Inc. Mr. Brancaccio received an undergraduate degree from Seton Hall University.
Thomas H. Adams Founder of Gen-Probe, Inc. and Genta, Inc., Thomas H. Adams is a businessperson who has been at the helm of 7 different companies and presently holds the position of Chairman & Chief Executive Officer of TrovaGene, Inc. Dr. Adams is also on the board of ContraVir Pharmaceuticals, Inc. and Gensignia Life Sciences, Inc. In his past career Dr. Adams was Executive Chairman of Clearbridge Biophotonics, Inc., Chief Executive Officer for Genta, Inc., Chairman & Chief Executive Officer for Leucadia Technologies, Inc., Chairman & Chief Executive Officer at Gen-Probe, Inc., Chairman & Chief Executive Officer at Iris Molecular Diagnostics, Inc., President at IRIS Personalized Medicine, Inc., Director-Research & Development at Baxter Laboratories, Inc., Director & Chief Technology Officer at Iris International, Inc. and Chief Technology Officer at Hybritech, Inc. Thomas H. Adams received a doctorate from the University of California, Riverside.
Tamar D. Howson Tamar D. Howson is on the board of International Partnership for Microbicides and 4 other companies. In the past Ms. Howson was Chief Executive Officer & Director at S*BIO Pte Ltd., Member of JSB-Partners LP, Senior VP & Director-Business Development at GlaxoSmithKline Plc and Senior VP & Director-Business Development at Smithkline Beecham Plc (a subsidiary of GlaxoSmithKline Plc), Vice President-Venture Investments at Johnston Associates, Inc., Senior VP-Corporate & Business Development at Bristol-Myers Squibb Co., Principal at Howson Associates Ltd., Executive Vice President-Corporate Development at Lexicon Pharmaceuticals, Inc. and Director-Worldwide Business Development at Squibb Corp. Tamar D. Howson received an MBA from Columbia University, an undergraduate degree from Technion-Israel Institute of Technology and a graduate degree from The City College of New York.
Robert T. Foster Robert T. Foster is a businessperson who founded Aurinia Pharmaceuticals, Inc. and Ciclofilin Pharmaceuticals, Inc. and who has been at the head of 5 different companies. Dr. Foster holds the position of President, Chief Executive Officer & Director at ContraVir Pharmaceuticals, Inc. and President & Chief Executive Officer at Isotechnika, Inc. Robert T. Foster is also on the board of Transcriptome Sciences and Member of Institute of Corporate Directors. He previously held the position of President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc. and President, Chief Executive Officer & Director at Isotechnika Pharma, Inc. (a subsidiary of Aurinia Pharmaceuticals, Inc.), Chief Executive Officer & Director at Ciclofilin Pharmaceuticals, Inc. and Associate Professor at the University of Alberta.
Arnold S. Lippa Founder of 6 different companies, including: DOV Pharmaceutical, Inc., Patch International, Inc. and Xintria Pharmaceutical Corp. Arnold S. Lippa and occupies the position of Executive Chairman of Xintria Pharmaceutical Corp. (which he founded in 2006), Executive Chairman, President & CEO at RespireRx Pharmaceuticals, Inc., Senior Managing Director at T. Morgen Capital LLC (which he founded in 2005) and Manager at Atypical BioVentures Fund, LLC (which he founded in 2004). He is also on the board of ContraVir Pharmaceuticals, Inc. and Senior Managing Director at Aurora Capital LLC and Manager of Atypical BioCapital Management LLC (he founded the company in 2004). In the past Arnold S. Lippa was Chairman & Chief Executive Officer of DOV Pharmaceutical, Inc. (he founded the company in 1995), President & Chief Operating Officer at Patch International, Inc. (he founded the company in 1984) and Director-Molecular Neurobiology at Wyeth Holdings LLC.
Gary S. Jacob Gary S. Jacob is a businessperson who has been at the helm of 7 different companies and currently holds the position of Chairman of ContraVir Pharmaceuticals, Inc., Chief Executive Officer & Director at Immuron Ltd. and President & Chief Executive Officer of Synergy Pharmaceuticals LLC. Dr. Jacob is also on the board of TrovaGene, Inc. In the past Dr. Jacob held the position of Chairman for Synergy Pharmaceuticals, Inc., Chairman of Synergy DE, President, Chief Executive & Scientific Officer at Callisto Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Pawfect Foods, Inc., Glycobiology Director at G.D. Searle & Co. Ltd., Director-Functional Genomics at Monsanto Co. and Manager-Searle Glycobiology Group at the University of Oxford. Gary S. Jacob received a doctorate from the University of Wisconsin and an undergraduate degree from the University of Missouri.
John Z. Sullivan-Bólyai Dr. John Z. Sullivan-Bólyai, MD, is Chief Medical Officer at ContraVir Pharmaceuticals, Inc. Dr. Sullivan-Bólyai was previously employed as Vice President-Clinical Research by Idenix Pharmaceuticals, Inc., Assistant Vice President-Research & Development by Valeant Pharmaceuticals International, Senior Medical Director by Biomeasure, Inc., Medical Director-Metabolic & Immune Therapy by Serono, Inc., Director-Clinical Science by Hoffmann-La Roche, Inc., and Vice President-Clinical Affairs by Anadys Pharmaceuticals, Inc. He received his undergraduate degree from Dartmouth College, a graduate degree from the University of Washington and a doctorate degree from the University of Washington.
James E. Sapirstein James E. Sapirstein founded Tobira Therapeutics, Inc. Currently, he is Chief Executive Officer & Director at ContraVir Pharmaceuticals, Inc. Mr. Sapirstein is also on the board of 5 other companies. In his past career Mr. Sapirstein occupied the position of Chief Executive Officer & Director at Alliqua BioMedical, Inc., Manager-International Operations at Eli Lilly & Co., Principal at Gilead Sciences, Inc., Director-International Marketing at Bristol-Myers Squibb Co., President, Chief Executive Officer & Director at Tobira Therapeutics, Inc., Principal at Hoffmann-La Roche, Inc. and Executive Vice President-Metabolic & Endocrinology at EMD Serono, Inc. James E. Sapirstein received an MBA from Fairleigh Dickinson University and an undergraduate degree from Ernest Mario School of Pharmacy.
John T. Cavan Currently, John T. Cavan occupies the position of Chief Financial & Accounting Officer for ContraVir Pharmaceuticals, Inc. Mr. Cavan is also on the board of Vantage Health System, Inc. In his past career Mr. Cavan held the position of Chief Accounting Officer of Stemline Therapeutics, Inc., Controller of AlgoRx Pharmaceuticals, Inc. and Chief Accounting Officer & Vice President of Aegerion Pharmaceuticals, Inc. He received an undergraduate degree from Iona College and an MBA from Seton Hall University.
Timothy M. Block Timothy M. Block founded Baruch S. Blumberg Institute and Hepatitis B Foundation. Dr. Block is on the board of ContraVir Pharmaceuticals, Inc. and Glycotest, Inc. and President & Chief Executive Officer of Pennsylvania Biotechnology Center of Bucks County, President for Baruch S. Blumberg Institute, President of Hepatitis B Foundation and Professor-Microbiology & Immunology at Drexel University College of Medicine.
Theresa Matkovits Theresa Matkovits is on the board of Aradigm Corp., BioSurplus, Inc. and Appili Therapeutics, Inc. and Chief Operating Officer at ContraVir Pharmaceuticals, Inc. In her past career she occupied the position of Head-Strategic Planning & Operations at Novartis AG and Vice President of The Medicines Co. Dr. Matkovits received an undergraduate degree from Alfred University and a doctorate from the University of Medicine & Dentistry of New Jersey.
Thomas H. Adams Founder of Gen-Probe, Inc. and Genta, Inc., Thomas H. Adams is a businessperson who has been at the helm of 7 different companies and presently holds the position of Chairman & Chief Executive Officer of TrovaGene, Inc. Dr. Adams is also on the board of ContraVir Pharmaceuticals, Inc. and Gensignia Life Sciences, Inc. In his past career Dr. Adams was Executive Chairman of Clearbridge Biophotonics, Inc., Chief Executive Officer for Genta, Inc., Chairman & Chief Executive Officer for Leucadia Technologies, Inc., Chairman & Chief Executive Officer at Gen-Probe, Inc., Chairman & Chief Executive Officer at Iris Molecular Diagnostics, Inc., President at IRIS Personalized Medicine, Inc., Director-Research & Development at Baxter Laboratories, Inc., Director & Chief Technology Officer at Iris International, Inc. and Chief Technology Officer at Hybritech, Inc. Thomas H. Adams received a doctorate from the University of California, Riverside.
Stephen Kilmer Stephen Kilmer holds the position of Head-Investor Relations at ContraVir Pharmaceuticals, Inc.